Issues
-
Cover Image
Cover Image
JCAD and LATS2 were stained immunohistochemically with specific primary antibodies and secondary antibodies labeled with Alexa-488 (green for JCAD) or Alexa-594 (red for LATS2). The nucleus was visualized by DAPI staining in blue. JCAD is overlaid with LATS2 in the proximity of the nucleus and appears in yellow. For details, see article by Ye and colleagues on page 5287. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Advances
Review
Meeting Report
New Advances and Challenges of Targeting Cancer Stem Cells
Priority Report
Molecular and Cellular Pathobiology
A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Tumor and Stem Cell Biology
Therapeutics, Targets, and Chemical Biology
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors
Integrated Systems and Technologies
Clinical Studies
Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing
Prevention and Epidemiology
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.